Literature DB >> 3485252

Reversibility of cardiac wall-motion abnormalities predicted by positron tomography.

J Tillisch, R Brunken, R Marshall, M Schwaiger, M Mandelkern, M Phelps, H Schelbert.   

Abstract

Positron emission tomography (PET) can be used with nitrogen-13-ammonia (13NH3) to estimate regional myocardial blood flow, and with fluorine-18-deoxyglucose (18FDG) to measure exogenous glucose uptake by the myocardium. We used PET to predict whether preoperative abnormalities in left ventricular wall motion in 17 patients who underwent coronary-artery bypass surgery were reversible. The abnormalities were quantified by radionuclide or contrast angiography or both, before and after grafting. PET images were obtained preoperatively. Abnormal wall motion in regions in which PET images showed preserved glucose uptake was predicted to be reversible, whereas abnormal motion in regions with depressed glucose uptake was predicted to be irreversible. According to these criteria, abnormal contraction in 35 of 41 segments was correctly predicted to be reversible (85 percent predictive accuracy), and abnormal contraction in 4 of 26 regions was correctly predicted to be irreversible (92 percent predictive accuracy). In contrast, electrocardiograms showing pathological Q waves in the region of asynergy predicted irreversibility in only 43 percent of regions. We conclude that PET imaging with 13NH3 to assess blood flow and 18FDG to assess the metabolic viability of the myocardium is an accurate method of predicting potential reversibility of wall-motion abnormalities after surgical revascularization.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485252     DOI: 10.1056/NEJM198604033141405

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  258 in total

1.  BMIPP compared with PET metabolism.

Authors:  E Tadamura; N Tamaki; T Kudoh; N Hattori; J Konishi
Journal:  Int J Card Imaging       Date:  1999-02

2.  Use of myocardial perfusion imaging to assess viability.

Authors:  M I Travin
Journal:  J Nucl Cardiol       Date:  2000 Jan-Feb       Impact factor: 5.952

Review 3.  Positron emission tomography and myocardial imaging.

Authors:  P G Camici
Journal:  Heart       Date:  2000-04       Impact factor: 5.994

Review 4.  Pathophysiology of myocardial hibernation. Implications for the use of dobutamine echocardiography to identify myocardial viability.

Authors:  J L Vanoverschelde; A Pasquet; B Gerber; J A Melin
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

Review 5.  Fluorine-18-deoxyglucose SPECT and coincidence imaging for myocardial viability: Clinical and technologic issues.

Authors:  V Dilsizian; S L Bacharach; M M Khin; M F Smith
Journal:  J Nucl Cardiol       Date:  2001 Jan-Feb       Impact factor: 5.952

6.  Proceedings of the 4th Invitational Wintergreen Conference. Wintergreen, Virginia, USA. July 12-14, 1998. Abstracts.

Authors: 
Journal:  J Nucl Cardiol       Date:  1999 Jan-Feb       Impact factor: 5.952

Review 7.  Cellular and molecular regulation of cardiac glucose transport.

Authors:  L H Young; D L Coven; R R Russell
Journal:  J Nucl Cardiol       Date:  2000 May-Jun       Impact factor: 5.952

8.  Exercise-induced myocardial ischemia: can this be imaged with F-18-fluorodeoxyglucose?

Authors:  D Jain; P H McNulty
Journal:  J Nucl Cardiol       Date:  2000 May-Jun       Impact factor: 5.952

Review 9.  PET radiopharmaceuticals used in viability studies in acute myocardial infarction: a literature survey.

Authors:  Liesbet Mesotten; Alex Maes; Frans Van de Werf; Luc Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2001-11-14       Impact factor: 9.236

Review 10.  Imaging myocardial metabolic remodeling.

Authors:  Robert J Gropler; Rob S B Beanlands; Vasken Dilsizian; E Douglas Lewandowski; Flordeliza S Villanueva; Maria Cecilia Ziadi
Journal:  J Nucl Med       Date:  2010-05-01       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.